Research: Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
7 Dec, 2017 | 22:06h | UTCHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant – New England Journal of Medicine (link to abstract – $ for full-text)
Quick Take Video Summary: Gene Therapy for Factor IX Deficiency (free)
Commentary: One-dose gene therapy produces clotting factor, safely stops bleeding in hemophilia B patients – MedicalXpress (free)